White House AI and Crypto Czar David Sacks on Thursday, June 18, 2026 signalled his opposition to a proposed regulatory model that would subject artificial intelligence systems to a pre-approval process modelled on the U.S. Food and Drug Administration, warning that such a framework would produce the very harms critics of unregulated AI fear most.

Context

Sacks posted on X: 'True. And this is exactly where an 'FDA for AI' will lead.' The remark was a reply affirming a point made by another user, though the original post is not reproduced here. The brevity of the statement — and the emphatic agreement — underscores how sharply Sacks views agency-led AI licensing as counterproductive rather than protective.

The phrase 'FDA for AI' refers to a regulatory proposal, debated in Washington DC policy circles since at least 2023, that would require AI systems to undergo mandatory government review and approval before deployment — analogous to how the FDA clears drugs and medical devices.

Policy Backdrop

The idea gained momentum after the release of large-scale AI models in 2023 and was embedded in the Biden administration's October 2023 executive order on AI safety, which directed federal agencies to develop sector-specific AI risk guidelines. Advocates argued that a centralised approval body would prevent harm from unvetted, high-stakes AI deployments in areas such as healthcare, finance, and critical infrastructure.

The Trump administration, which took office for its second term in 2025, has moved in the opposite direction, prioritising deregulation of both AI and cryptocurrency sectors. Sacks, as the administration's designated AI and Crypto Czar, has been the principal voice articulating this lighter-touch philosophy, arguing that heavy pre-market regulation would cede American technological leadership to rivals, particularly China and Europe.

The European Union's AI Act, which entered into force in 2024, is frequently cited in this debate as a cautionary example of compliance-heavy oversight that critics say slows deployment and burdens startups disproportionately.

Stakeholders and Impact

The debate has direct consequences for AI startups, large technology companies, and venture investors — including Sacks's own firm, Craft Ventures — that have billions of dollars deployed in AI infrastructure and applications. A mandatory pre-approval regime would add significant cost and delay to product cycles, potentially concentrating market power in well-capitalised incumbents who can absorb compliance overhead.

Consumer-safety advocates and AI-risk researchers, on the other hand, contend that deploying powerful AI systems without independent review creates systemic risks that the market alone cannot price or prevent. The tension between these two positions is now a defining fault line in U.S. technology policy.

For India, which is actively shaping its own AI governance framework through bodies such as the Ministry of Electronics and Information Technology, the direction the United States takes will carry significant weight — both as a model and as a signal about where global AI investment and talent will flow.

What's Next

Congressional committees in Washington DC are expected to take up AI-specific legislation in 2026, with proposals ranging from voluntary safety commitments to mandatory licensing regimes. Sacks's public posture suggests the Trump administration will oppose any bill that creates a pre-market approval gate for AI products.

Executive orders clarifying federal AI oversight roles are also being watched closely. How the administration defines the boundary between permissible innovation and regulated risk will shape the commercial AI landscape for years, and Sacks's continued willingness to engage the debate publicly suggests the White House intends to remain an active participant in setting those terms.